Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Temsirolimus Resistance”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Testing effectiveness (Phase 2)Ended earlyNCT02565901
What this trial is testing

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v7+1 more
University of Washington 28
Early research (Phase 1)Study completedNCT00703170
What this trial is testing

Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies

Who this might be right for
Resistant Solid Malignancies
Washington University School of Medicine 28
Early research (Phase 1)Study completedNCT01522820
What this trial is testing

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Who this might be right for
Anaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic Oligodendroglioma+62 more
Roswell Park Cancer Institute 18
Early research (Phase 1)Study completedNCT00703625
What this trial is testing

Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies

Who this might be right for
Resistant Solid Malignancies
Washington University School of Medicine 26
Testing effectiveness (Phase 2)Looking for participantsNCT05144698
What this trial is testing

RAPA-201 Therapy of Solid Tumors

Who this might be right for
Solid TumorSmall Cell and Non-small Cell Lung CancerHead and Neck Cancer+6 more
Rapa Therapeutics LLC 37
Testing effectiveness (Phase 2)Study completedNCT01797120
What this trial is testing

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

Who this might be right for
Metastatic Breast Cancer
PrECOG, LLC. 131
Testing effectiveness (Phase 2)Ended earlyNCT01239368
What this trial is testing

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

Who this might be right for
Myeloma, Plasma-CellMyeloma-MultipleMyelomatosis
National Cancer Institute (NCI) 34
Testing effectiveness (Phase 2)Study completedNCT01083368
What this trial is testing

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Who this might be right for
Prostate Cancer
Case Comprehensive Cancer Center 22
Testing effectiveness (Phase 2)Study completedNCT01298713
What this trial is testing

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

Who this might be right for
Breast NeoplasmsmTor Protein
ARCAGY/ GINECO GROUP 111
Early research (Phase 1)Study completedNCT03646240
What this trial is testing

ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)

Who this might be right for
Epilepsy Intractable
Seattle Children's Hospital 14
Testing effectiveness (Phase 2)Study completedNCT01798446
What this trial is testing

A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus

Who this might be right for
Renal Cell CarcinomaNonclear CellTemsirolimus Resistance
Seoul National University Hospital 41
Not applicableStudy completedNCT02444390
What this trial is testing

Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor

Who this might be right for
Metastatic Breast Cancer
UNICANCER 150
Not applicableLooking for participantsNCT07646171
What this trial is testing

EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)

Who this might be right for
Hormone Receptor Positive Breast Cancer
Tel-Aviv Sourasky Medical Center 19
Testing effectiveness (Phase 2)Study completedNCT04176380
What this trial is testing

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Who this might be right for
Relapsed, Refractory Multiple Myeloma
Rapa Therapeutics LLC 15
Not applicableLooking for participantsNCT05233722
What this trial is testing

MTOR as Mediator of Insulin Sensitivity Study

Who this might be right for
Insulin Sensitivity
University of Copenhagen 10
Testing effectiveness (Phase 2)Study completedNCT01206036
What this trial is testing

CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)

Who this might be right for
Prostatic Neoplasms
Central European Society for Anticancer Drug Research 19
Testing effectiveness (Phase 2)Looking for participantsNCT07191353
What this trial is testing

Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women

Who this might be right for
HealthyOsteopeniaOsteoporosis Risk
Odense University Hospital 148
Testing effectiveness (Phase 2)Study completedNCT00919035
What this trial is testing

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Oncology Specialists, S.C. 21
Early research (Phase 1)Study completedNCT01054313
What this trial is testing

Docetaxel and Sirolimus in Patients With Advanced Malignancies

Who this might be right for
Advanced Cancer
M.D. Anderson Cancer Center 103
Testing effectiveness (Phase 2)Study completedNCT01026623
What this trial is testing

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerProstate AdenocarcinomaRecurrent Prostate Carcinoma+1 more
National Cancer Institute (NCI) 16
Next Page